Ruxolitinib suppresses liver fibrosis progression and accelerates fibrosis reversal via selectively targeting Janus kinase 1/2

BACKGROUND: JAK1 and JAK2 have been implicated in fibrosis and cancer as a fibroblast-related marker; however, their role in liver fibrosis has not been elucidated. Here, we aim to determine the effect and underlying mechanism of JAK1/2 inhibition on liver fibrosis and hepatic stellate cells (HSCs)...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Zhenghui, Liu, Xinhui, Zhang, Wan, Luo, Yue, Xiao, Hua, Liu, Yun, Dai, Guanqi, Hong, Jian, Li, Aimin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8981941/
https://www.ncbi.nlm.nih.gov/pubmed/35382859
http://dx.doi.org/10.1186/s12967-022-03366-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8981941/
https://www.ncbi.nlm.nih.gov/pubmed/35382859
http://dx.doi.org/10.1186/s12967-022-03366-y

Ejemplares similares